1. Show article details.

    The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial

    Benzinga – 9:03 AM ET 06/21/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours: A panel of the FDA's outside experts voted 9-3 that Acadia Pharmaceuticals Inc's  pimavanserin doesn't appear to be effective at treating patients with Alzheimer's-related psychosis. The drug, Nuplazid, is already indicated for Parkinson's-related psychosis.

  2. Show article details.

    BRIEF-XBiotech Announces Successful Completion Of Phase I Portion Of Pancreatic Cancer Study

    Reuters – 9:16 AM ET 06/20/2022

    XBiotech Inc (XBIT): * XBIOTECH ANNOUNCES SUCCESSFUL COMPLETION OF PHASE I PORTION OF PANCREATIC CANCER STUDY. * XBiotech Inc (XBIT) - ENROLLMENT IN PHASE II PORTION IS COMMENCING IMMEDIATELY FOR NATRUNIX Source text for Eikon: Further company coverage:

  3. Show article details.

    XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study

    GlobeNewswire – 9:00 AM ET 06/20/2022

    XBiotech Inc. (XBIT) announced today it successfully completed the Phase I portion of its 1-BETTER study, a Phase I/II randomized, double-blind, placebo-controlled clinical study to evaluate its anti-cancer drug Natrunix in combination with chemotherapy for treating pancreatic cancer. Thirty leading cancer centers across the United States are involved in the Phase I/II study.

  4. Show article details.

    Stocks That Hit 52-Week Lows On Thursday

    Benzinga – 1:27 PM ET 06/02/2022

      During the Thursday's session, 100 stocks hit new 52-week lows. On Thursday, the following stocks set new 52-week lows: Be sure to monitor Benzinga for the news traders need!

  5. Show article details.

    Stocks That Hit 52-Week Lows On Tuesday

    Benzinga – 12:13 PM ET 05/24/2022

      On Tuesday, 540 companies set new 52-week lows. These stocks set new 52-week lows on Tuesday: Be sure to monitor Benzinga for the news traders need!

  6. Show article details.

    Stocks That Hit 52-Week Lows On Monday

    Benzinga – 1:59 PM ET 05/16/2022

      On Monday, 198 companies reached new 52-week lows. On Monday, the following stocks broke to new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.

  7. Show article details.

    74 Biggest Movers From Yesterday

    Benzinga – 5:19 AM ET 04/29/2022

    74 Biggest Movers From Yesterday

  8. Show article details.

    12 Health Care Stocks Moving In Thursday's Intraday Session

    Benzinga – 3:18 PM ET 04/28/2022

      This article was generated by Benzinga's automated content engine and reviewed by an editor.

  9. Show article details.

    Why Are XBiotech Shares Trading Higher Today

    Benzinga – 2:53 PM ET 04/28/2022

    Why Are XBiotech Shares Trading Higher Today

  10. Show article details.

    BRIEF-XBiotech Announces French National Agency Approval For Cancer Treatment Study

    Reuters – 9:44 AM ET 04/28/2022

    XBiotech Inc (XBIT): * XBIOTECH ANNOUNCES FRENCH NATIONAL AGENCY APPROVAL AND NATIONAL CANCER INSTITUTE FUNDING TO SUPPORT PHASE I/II/III CLINICAL STUDY FOR NATRUNIX™ IN COMBINATION WITH TRIFLURIDINE/TIPIRACIL FOR TREATMENT OF METASTATIC COLORECTAL CANCER.

  11. Show article details.

    XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer

    GlobeNewswire – 9:00 AM ET 04/28/2022

    XBiotech (XBIT) announced today that the French National Agency for the Safety of Medicines and Health Products [L'Agence nationale de sécurité du médicament et des produits de santé] approved the launch of a multicenter randomized clinical study for XBiotech’s candidate cancer treatment Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer.

  12. Show article details.

    Stocks That Hit 52-Week Lows On Tuesday

    Benzinga – 1:44 PM ET 04/26/2022

      During Tuesday, 581 stocks hit new 52-week lows. Meta Platforms was the biggest company on a market cap basis to set a new 52-week low. The smallest company by market cap to set a new 52-week low was AnPac Bio-Medical Science. During Tuesday, the following stocks broke to new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.

  13. Show article details.

    Stocks That Hit 52-Week Lows On Monday

    Benzinga – 12:01 PM ET 04/25/2022

      On Monday, 721 companies achieved new lows for the year. During Monday, the following stocks set new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.

  14. Show article details.

    Stocks That Hit 52-Week Lows On Thursday

    Benzinga – 1:54 PM ET 04/21/2022

      On Thursday, 236 companies hit new 52-week lows. Stocks that set new 52-week lows are as follows: Be sure to monitor Benzinga for the news traders need!

  15. Show article details.

    Stocks That Hit 52-Week Lows On Monday

    Benzinga – 11:40 AM ET 04/18/2022

      On Monday, 466 companies hit new 52-week lows. Stocks that set new 52-week lows on Monday are as follows:   Be sure to monitor Benzinga for the news traders need!

  16. Show article details.

    Stocks That Hit 52-Week Lows On Thursday

    Benzinga – 2:10 PM ET 03/31/2022

      On Thursday, 92 companies hit new 52-week lows. Here is a list of stocks that set new 52-week lows on Thursday: Be sure to stay with Benzinga for further updates and market-moving news.

  17. Show article details.

    Stocks That Hit 52-Week Lows On Monday

    Benzinga – 12:11 PM ET 03/14/2022

      On Monday, 671 companies achieved new lows for the year. Here is a list of stocks that set new 52-week lows on Monday: Be sure to monitor Benzinga for the news traders need!

  18. Show article details.

    XBiotech Inks Clinical Manufacturing Deal

    GlobeNewswire – 9:00 AM ET 02/02/2022

    XBiotech Inc. (XBIT) announced today that it executed Manufacturing Agreement with Janssen Research & Development, LLC to manufacture clinical product, including Bermekimab, a True Human monoclonal antibody sold to Janssen by XBiotech (XBIT) in December 2019. XBiotech (XBIT) discovers and develops therapeutics based on antibodies it identifies from donors with natural human immunity against disease.

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • May
    10

    XBIT announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.